TABLE 3.

Future directions in epidemiology and risk factors

➢ Define rate and factors increasing the risk of BKPyV-DNAemia/-nephropathy in ABO-incompatible living donor kidney transplant recipients

➢ Define the effect of mTOR inhibitors on endpoints in randomized clinical trials regarding rates and course of BKPyV-DNAemia/-nephropathy

➢ Evaluate the role of high Torque teno virus loads as a risk factor of BKPyV-DNAemia/-nephropathy

➢ Assess whether optimizing immunosuppression reduces BKPyV-DNAemia/-nephropathy rates in recipients with low neutralizing antibodies against the donor BKPyV serotype

➢ Evaluate the role of BKPyV-DNAuria for recurrent BKPyV-DNAemia/-nephropathy after retransplantation of patients with a failed transplant from BKPyV-nephropathy

BKPyV, BK polyomavirus; mTOR, mammalian target of rapamycin.